Molecular mechanisms of acrolein-mediated myelin destruction in CNS trauma and disease

References

• Poliak S, Peles E. The local differentiation of myelinated axons at nodes of Ranvier. Nat Rev Neurosci 2003;4:968–980.
   PubMed Web of Science ®Google Scholar
• McDonald JW, Belegu V. Demyelination and remyelination after spinal cord injury. J Neurotrauma 2006;23:345–359.
   PubMed Web of Science ®Google Scholar
• Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009;8:280–291.
   PubMed Web of Science ®Google Scholar
• Blight AR. Delayed demyelination and macrophage invasion: A candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985;2:299–315.
   PubMedGoogle Scholar
• Totoiu MO, Keirstead HS. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 2005;486:373–383.
   PubMed Web of Science ®Google Scholar
• Tully M, Shi R. New insights in the pathogenesis of multiple sclerosis—role of acrolein in neuronal and myelin damage. Int J Mol Sci 2013;14:20037–20047.
   PubMedGoogle Scholar
• Rudick RA, Trapp BD. Gray-matter injury in multiple sclerosis. N Engl J Med 2009;361:1505–1506.
   PubMedGoogle Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372: 1502–1517.
   PubMed Web of Science ®Google Scholar
• Jensen JM, Shi R. Effects of 4-aminopyridine on stretched mammalian spinal cord: the role of potassium channels in axonal conduction. J Neurophysiol 2003;90:2334–2340.
   PubMedGoogle Scholar
• Ouyang H, Sun W, Fu Y, Li J, Cheng JX, Nauman E, Shi R. Compression induces acute demyelination and potassium channel exposure in spinal cord. J Neurotrauma 2010;27: 1109–1120.
   PubMedGoogle Scholar
• Sun W, Fu Y, Shi Y, Cheng JX, Cao P, Shi R. Paranodal myelin damage after acute stretch in Guinea pig spinal cord. J Neurotrauma 2012;29:611–619.
   PubMedGoogle Scholar
• Kandel ER, Schwartz JH, Jessell TM. Principles of neural science. 4th ed. New York: McGraw-hill; 2000.
   Google Scholar
• Shi R, Sun W. Potassium channel blockers as an effective treatment to restore impulse conduction in injured axons. Neurosci Bull 2011;27:36–44.
   PubMedGoogle Scholar
• Sun W, Smith D, Fu Y, Cheng JX, Bryn S, Borgens R, Shi R. Novel potassium channel blocker, 4-AP-3-MeOH, inhibits fast potassium channels and restores axonal conduction in injured guinea pig spinal cord white matter. J Neurophysiol 2010;103:469–478.
   PubMedGoogle Scholar
• Leung G, Sun W, Brookes S, Smith D, Shi R. Potassium channel blocker, 4-Aminopyridine-3-Methanol, restores axonal conduction in spinal cord of an animal model of multiple sclerosis. Exp Neurol 2011;227:232–235.
   PubMedGoogle Scholar
• Shi R, Blight AR. Compression injury of mammalian spinal cord in vitro and the dynamics of action potential conduction failure. J Neurophysiol 1996;76:1572–1580.
   PubMed Web of Science ®Google Scholar
• Bostock H, Sherratt RM, Sears TA. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature 1978;274:385–387.
   PubMed Web of Science ®Google Scholar
• Targ EF, Kocsis JD. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985;328:358–361.
   PubMed Web of Science ®Google Scholar
• Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22:47–52.
   PubMed Web of Science ®Google Scholar
• Blight AR, DeCrescito V. Morphometric analysis of experimental spinal cord injury in the cat: the relation of injury intensity to survival of myelinated axons. Neuroscience 1986;19:321–341.
   PubMed Web of Science ®Google Scholar
• Blight AR, Gruner JA. Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J Neurol Sci 1987;82:145–159.
   PubMedGoogle Scholar
• Young W. Secondary injury mechanisms in acute spinal cord injury. J Emergency Med 1993;11:13–22.
   PubMedGoogle Scholar
• Blight AR. Effects of silica on the outcome from experimental spinal cord injury: Implication of macrophages in secondary tissue damage. Neuroscience 1994;60:263–273.
   PubMedGoogle Scholar
• Babbs CF, Shi R. Subtle paranodal injury slows impulse conduction in a mathematical model of myelinated axons. PLoS One 2013;8:e67767.
   PubMedGoogle Scholar
• Shi R, Blight AR. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997;77: 553–562.
   PubMed Web of Science ®Google Scholar
• Shi R, Kelly TM, Blight AR. Conduction block in acute and chronic spinal cord injury: Different dose-response characteristics for reversal by 4-Aminopyridine. Exp Neurol 1997; 148:495–501.
   PubMed Web of Science ®Google Scholar
• Blight AR. Morphometric analysis of a model of spinal cord injury in guinea pigs, with behavioral evidence of delayed secondary pathology. J Neurol Sci 1991;103:156–171.
   PubMed Web of Science ®Google Scholar
• Shi Y, Kim S, Huff TB, Borgens RB, Park K, Shi R, Cheng J-X. Effective repair of traumatically injured spinal cord by nanoscale block copolymer micelles. Nat Nanotechnol 2010;5:80–87.
   PubMed Web of Science ®Google Scholar
• Waxman SG. Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 1982;306:1529–1533.
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun W, McBride JJ, Cheng JX, Shi R. Acrolein induces myelin damage in mammalian spinal cord. J Neurochem 2011;117:554–564.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9: 69–92.
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81–128.
   PubMed Web of Science ®Google Scholar
• Seiler N. Oxidation of polyamines and brain injury. Neurochem Res 2000;25:471–490.
   PubMed Web of Science ®Google Scholar
• Stevens JF, Maier CS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol Nutr Food Res 2008;52:7–25.
   PubMed Web of Science ®Google Scholar
• Faroon O, Roney N, Taylor J, Ashizawa A, Lumpkin MH, Plewak DJ. Acrolein health effects. Toxicol Ind Health 2008;24:447–490.
   PubMed Web of Science ®Google Scholar
• Kehrer JP, Biswal SS. The molecular effects of acrolein. Toxicol Sci 2000;57:6–15.
   PubMed Web of Science ®Google Scholar
• Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med 1999;9:109–113.
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005;35: 609–662.
   PubMed Web of Science ®Google Scholar
• Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, et al. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J Biol Chem 2007; 282:19666–19675.
   PubMed Web of Science ®Google Scholar
• Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 1998;273:16058–16066.
   PubMed Web of Science ®Google Scholar
• Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci U S A 1998;95: 4882–4887.
   PubMed Web of Science ®Google Scholar
• Ghilarducci DP, Tjeerdema RS. Fate and effects of acrolein. Rev Environ Contam Toxicol 1995;144:95–146.
   PubMed Web of Science ®Google Scholar
• Dreosti IE. 1991. Trace elements, micronuteitions, and free radicals. Vol. 149. Clifton, NJ: Human Press.
   Google Scholar
• Roots R, Okada S. Estimation of life times and diffusion distances of radicals involved in x-ray-induced DNA strand breaks of killing of mammalian cells. Radiat Res 1975;64: 306–320.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. 1999. Free radicals in biology and medicine. Oxford: Oxford University Press.
   Google Scholar
• Hall ED, Springer JE. Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 2004;1:80–100.
   PubMedGoogle Scholar
• Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953–1971.
   PubMed Web of Science ®Google Scholar
• Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury. J Neurochem 2009;111:1348–1356.
   PubMed Web of Science ®Google Scholar
• Shi R, Luo L. The role of acrolein in spinal cord injury. Appl Neurol 2006;2:22–27.
   PubMedGoogle Scholar
• Shi R, Rickett T, Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Mol Nutr Food Res 2011;55: 1320–1331.
   PubMed Web of Science ®Google Scholar
• Tully M, Zheng L, Shi R. Acrolein detection: potential theranostic utility in multiple sclerosis and spinal cord injury. Expert Rev Neurother 2014;14:679–685.
   PubMed Web of Science ®Google Scholar
• Adams JD Jr., Klaidman LK. Acrolein-induced oxygen radical formation. Free Radic Biol Med 1993;15:187–193.
   PubMed Web of Science ®Google Scholar
• Luo J, Shi R. Acrolein induces axolemmal disruption, oxidative stress, and mitochondrial impairment in spinal cord tissue. Neurochem Int 2004;44:475–486.
   PubMed Web of Science ®Google Scholar
• Luo J, Shi R. Acrolein induces oxidative stress in brain mitochondria. Neurochem Int 2005;46:243–252.
   PubMed Web of Science ®Google Scholar
• Hamann K, Durkes A, Ouyang H, Uchida K, Pond A, Shi R. Critical role of acrolein in secondary injury following ex vivo spinal cord trauma. J Neurochem 2008;107:712–721.
   PubMedGoogle Scholar
• Zheng L, Park J, Walls M, Tully M, Jannasch A, Cooper B, Shi R. Determination of urine 3-HPMA, a stable acrolein metabolite in a rat model of spinal cord injury. J Neurotrauma 2013;30:1334–1341.
   PubMedGoogle Scholar
• Leung G, Sun W, Zheng L, Brookes S, Tully M, Shi R. Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse. Neuroscience 2011;173: 150–155.
   PubMed Web of Science ®Google Scholar
• Picklo MJ, Montine TJ. Acrolein inhibits respiration in isolated brain mitochondria. Biochim Biophys Acta 2001; 1535:145–152.
   PubMed Web of Science ®Google Scholar
• Shi R, Luo J, Peasley MA. Acrolein inflicts axonal membrane disruption and conduction loss in isolated guinea pig spinal cord. Neuroscience 2002;115:337–340.
   PubMed Web of Science ®Google Scholar
• Liu-Snyder P, McNally H, Shi R, Borgens RB. Acrolein-mediated mechanisms of neuronal death. J Neurosci Res 2006;84:209–218.
   PubMed Web of Science ®Google Scholar
• Luo J, Uchida K, Shi R. Accumulation of acrolein-protein adducts after traumatic spinal cord injury. Neurochem Res 2005;30:291–295.
   PubMedGoogle Scholar
• Due MR, Park J, Zheng L, Walls M, Allette YM, White FA, Shi R. Acrolein involvement in sensory and behavioral hypersensitivity following spinal cord injury in the rat. J Neurochem 2014;128:776–786.
   PubMed Web of Science ®Google Scholar
• Park J, Zheng L, Marquis A, Walls M, Duerstock B, Pond A, et al. Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage. J Neurochem 2014;129:339–349.
   PubMed Web of Science ®Google Scholar
• Hamann K, Nehrt G, Ouyang H, Duerstock B, Shi R. Hydralazine inhibits compression and acrolein-mediated injuries in ex vivo spinal cord. J Neurochem 2008;104: 708–718.
   PubMed Web of Science ®Google Scholar
• Wang H, Fu Y, Zickmund P, Shi R, Cheng JX. Coherent anti-stokes Raman scattering imaging of axonal myelin in live spinal tissues. Biophys J 2005;89:581–591.
   PubMed Web of Science ®Google Scholar
• Boggs JM. Myelin basic protein: A multifunctional protein. Cell Mol Life Sci 2006;63:1945–1961.
   PubMed Web of Science ®Google Scholar
• Readhead C, Takasashi N, Shine HD, Saavedra R, Sidman R, Hood L. Role of myelin basic protein in the formation of central nervous system myelin. Ann N Y Acad Sci 1990;605:280–285.
   PubMedGoogle Scholar
• Einheber S, Zanazzi G, Ching W, Scherer S, Milner TA, Peles E, Salzer JL. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 1997;139:1495–1506.
   PubMed Web of Science ®Google Scholar
• Tao-Cheng JH, Rosenbluth J. Axolemmal differentiation in myelinated fibers of rat peripheral nerves. Brain Res 1983;285:251–263.
   PubMedGoogle Scholar
• Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, Hemperly J, et al. Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. J Neurosci 2000;20:8354–8364.
   PubMed Web of Science ®Google Scholar
• Menegoz M, Gaspar P, Le Bert M, Galvez T, Burgaya F, Palfrey C, et al. Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron 1997;19:319–331.
   PubMedGoogle Scholar
• Denisenko-Nehrbass N, Oguievetskaia K, Goutebroze L, Galvez T, Yamakawa H, Ohara O, et al. Protein 4.1B associates with both Caspr/paranodin and Caspr2 at paranodes and juxtaparanodes of myelinated fibres. Eur J Neurosci 2003;17:411–416.
   PubMedGoogle Scholar
• Ogawa Y, Schafer DP, Horresh I, Bar V, Hales K, Yang Y, et al. Spectrins and ankyrinB constitute a specialized paranodal cytoskeleton. J Neurosci 2006;26:5230–5239.
   PubMedGoogle Scholar
• Kontrogianni-Konstantopoulos A, Frye CS, Benz EJ Jr., Huang SC. The prototypical 4.1R–10-kDa domain and the 4.1 g-10-kDa paralog mediate fodrin-actin complex formation. J Biol Chem 2001;276:20679–20687.
   PubMedGoogle Scholar
• Fraser PE, Deber CM. Surface accessibility of 13C-labeled lysine residues in membrane-bound myelin basic protein. J Biol Chem 1984;259:8689–8692.
   PubMedGoogle Scholar
• Yokoyama A, Igarashi K, Sato T, Takagi K, Otsuka IM, Shishido Y, et al. Identification of myelin transcription factor 1 (MyT1) as a subunit of the neural cell type-specific lysine-specific demethylase 1 (LSD1) complex. J Biol Chem 2014;289:18152–18162.
   PubMed Web of Science ®Google Scholar
• Gibson BW, Gilliom RD, Whitaker JN, Biemann K. Amino acid sequence of human myelin basic protein peptide 45-89 as determined by mass spectrometry. J Biol Chem 1984;259:5028–5031.
   PubMedGoogle Scholar
• Wang KK. Calpain and caspase: can you tell the difference? Trends Neurosci 2000;23:20–26.
   PubMed Web of Science ®Google Scholar
• Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83:731–801.
   PubMed Web of Science ®Google Scholar
• Wolswijk G, Balesar R. Changes in the expression and localization of the paranodal protein Caspr on axons in chronic multiple sclerosis. Brain 2003;126:1638–1649.
   PubMed Web of Science ®Google Scholar
• Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006;439:988–992.
   PubMed Web of Science ®Google Scholar
• Lima RR, Guimaraes-Silva J, Oliveira JL, Costa AM, Souza-Rodrigues RD, Dos Santos CD, et al. Diffuse axonal damage, myelin impairment, astrocytosis and inflammatory response following microinjections of NMDA into the rat striatum. Inflammation 2008;31:24–35.
   PubMedGoogle Scholar
• Fu Y, Sun W, Shi Y, Shi R, Cheng JX. Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction. PLoS One 2009;4:e6705.
   PubMed Web of Science ®Google Scholar
• Nicole O, Ali C, Docagne F, Plawinski L, MacKenzie ET, Vivien D, Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci 2001;21:3024–3033.
   PubMed Web of Science ®Google Scholar
• Shields DC, Schaecher KE, Saido TC, Banik NL. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A 1999;96:11486–11491.
   PubMedGoogle Scholar
• Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A 1998;95:5768–5772.
   PubMedGoogle Scholar
• Stover JF, Pleines UE, Morganti-Kossmann MC, Kossmann T, Lowitzsch K, Kempski OS. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997;27:1038–1043.
   PubMed Web of Science ®Google Scholar
• Blanc EM, Keller JN, Fernandez S, Mattson MP. 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia 1998;22:149–160.
   PubMed Web of Science ®Google Scholar
• Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1–42. J Neurochem 2001;78:413–416.
   PubMed Web of Science ®Google Scholar
• Springer JE, Azbill RD, Mark RJ, Begley JG, Waeg G, Mattson MP. 4-hydroxynonenal, a lipid peroxidation product, rapidly accumulates following traumatic spinal cord injury and inhibits glutamate uptake. J Neurochem 1997; 68:2469–2476.
   PubMed Web of Science ®Google Scholar
• Trotti D, Rizzini BL, Rossi D, Haugeto O, Racagni G, Danbolt NC, Volterra A. Neuronal and glial glutamate transporters possess an SH-based redox regulatory mechanism. Eur J Neurosci 1997;9:1236–1243.
   PubMed Web of Science ®Google Scholar
• Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008;274:48–53.
   PubMed Web of Science ®Google Scholar
• Burcham PC, Kerr PG, Fontaine F. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep 2000;5:47–49.
   PubMed Web of Science ®Google Scholar
• Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology 2002;181–182:229–236.
   PubMed Web of Science ®Google Scholar
• Burcham PC, Fontaine FR, Kaminskas LM, Petersen DR, Pyke SM. Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein- mediated toxicity. Mol Pharmacol 2004;65:655–664.
   PubMedGoogle Scholar
• Burcham PC, Pyke SM. Hydralazine inhibits rapid acrolein-induced protein oligomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection. Mol Pharmacol 2006;69: 1056–1065.
   PubMed Web of Science ®Google Scholar
• Kaminskas LM, Pyke SM, Burcham PC. Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. Org Biomol Chem 2004;2:2578–2584.
   PubMedGoogle Scholar
• Liu-Snyder P, Borgens RB, Shi R. Hydralazine rescues PC12 cells from acrolein-mediated death. J Neurosci Res 2006; 84:219–227.
   PubMed Web of Science ®Google Scholar
• Hubli M, Gee CM, Krassioukov AV. Refined assessment of blood pressure instability after spinal cord injury. Am J Hypertens 2015;28:173–181.
   PubMed Web of Science ®Google Scholar
• Zhu C, Galea M, Livote E, Signor D, Wecht JM. A retrospective chart review of heart rate and blood pressure abnormalities in veterans with spinal cord injury. J Spinal Cord Med 2013;36:463–475.
   PubMed Web of Science ®Google Scholar
• Gunduz H, Binak DF. Autonomic dysreflexia: an important cardiovascular complication in spinal cord injury patients. Cardiol J 2012;19:215–219.
   PubMedGoogle Scholar
• Galligan JJ, Smathers RL, Fritz KS, Epperson LE, Hunter LE, Petersen DR. Protein carbonylation in a murine model for early alcoholic liver disease. Chem Res Toxicol 2012; 25:1012–1021.
   PubMedGoogle Scholar